Skip to main content

Articles

Page 11 of 39

  1. Ubiquitin-conjugating enzyme E2 M (UBE2M) and ubiquitin-conjugating enzyme E2 F (UBE2F) are the two NEDD8-conjugating enzymes of the neddylation pathway that take part in posttranslational modification and cha...

    Authors: Yi-Chao Zheng, Yan-Jia Guo, Bo Wang, Chong Wang, M. A. A. Mamun, Ya Gao and Hong-Min Liu
    Citation: Journal of Hematology & Oncology 2021 14:57
    Content type: Review Published on:

  2. Mixed lineage leukemia 1 (MLL1, also known as MLL or KMT2A) is an important transcription factor and histone-H3 lysine-4 (H3K4) methyltransferase. It is a master regulator for transcription of important genes ...

    Authors: Xin Li and Yongcheng Song
    Citation: Journal of Hematology & Oncology 2021 14:56
    Content type: Review Published on:

  3. The TGF-β signaling pathway governs key cellular processes under physiologic conditions and is deregulated in many pathologies, including cancer. TGF-β is a multifunctional cytokine that acts in a cell- and co...

    Authors: Byung-Gyu Kim, Ehsan Malek, Sung Hee Choi, James J. Ignatz-Hoover and James J. Driscoll
    Citation: Journal of Hematology & Oncology 2021 14:55
    Content type: Review Published on:

  4. N6-methyladenosine (m6A) modification is the most prevalent modification in eukaryotic RNAs while accumulating studies suggest that m6A aberrant expression plays an important role in cancer. HNRNPA2B1 is a m6A...

    Authors: Fengjie Jiang, Xiaozhu Tang, Chao Tang, Zhen Hua, Mengying Ke, Chen Wang, Jiamin Zhao, Shengyao Gao, Artur Jurczyszyn, Siegfried Janz, Meral Beksac, Fenghuang Zhan, Chunyan Gu and Ye Yang
    Citation: Journal of Hematology & Oncology 2021 14:54
    Content type: Letter to the Editor Published on:

  5. Non-T-cell depleted haploidentical hematopoietic stem cell transplantation (HaploSCT) is being increasingly used in acute lymphoblastic leukemia (ALL) with improving patient outcomes. We have recently reported...

    Authors: Arnon Nagler, Myriam Labopin, Mohamed Houhou, Mahmoud Aljurf, Ashrafsadat Mousavi, Rose-Marie Hamladji, Mohsen Al Zahrani, Sergey Bondarenko, Mutlu Arat, Emanuele Angelucci, Yener Koc, Zafer Gülbas, Simona Sica, Jean Henri Bourhis, Jonathan Canaani, Eolia Brissot…
    Citation: Journal of Hematology & Oncology 2021 14:53
    Content type: Research Published on:

  6. Frameshifts in the Calreticulin (CALR) exon 9 provide a recurrent driver mutation of essential thrombocythemia (ET) and primary myelofibrosis among myeloproliferative neoplasms (MPNs). Here, we generated knock-in...

    Authors: Keiji Minakawa, Tetsuro Yokokawa, Koki Ueda, Osamu Nakajima, Tomofumi Misaka, Yusuke Kimishima, Kento Wada, Yusuke Tomita, Saori Miura, Yuka Sato, Kosaku Mimura, Koichi Sugimoto, Kazuhiko Nakazato, Kenneth E. Nollet, Kazuei Ogawa, Takayuki Ikezoe…
    Citation: Journal of Hematology & Oncology 2021 14:52
    Content type: Letter to the Editor Published on:

  7. Despite survival improvements achieved over the last two decades, prostate cancer remains lethal at the metastatic castration-resistant stage (mCRPC) and new therapeutic approaches are needed. Germinal and/or ...

    Authors: Diego Teyssonneau, Henri Margot, Mathilde Cabart, Mylène Anonnay, Paul Sargos, Nam-Son Vuong, Isabelle Soubeyran, Nicolas Sevenet and Guilhem Roubaud
    Citation: Journal of Hematology & Oncology 2021 14:51
    Content type: Review Published on:

  8. The recent approvals by the Food and Drug Administration several tumor-agnostic drugs have resulted in a paradigm shift in cancer treatment from an organ/histology-specific strategy to biomarker-guided approac...

    Authors: Leylah M. Drusbosky, Estelamari Rodriguez, Richa Dawar and Chukwuemeka V. Ikpeazu
    Citation: Journal of Hematology & Oncology 2021 14:50
    Content type: Review Published on:

  9. Until recently, acute myeloid leukemia (AML) patients used to have limited treatment options, depending solely on cytarabine + anthracycline (7 + 3) intensive chemotherapy and hypomethylating agents. Allogenei...

    Authors: Hongtao Liu
    Citation: Journal of Hematology & Oncology 2021 14:49
    Content type: Review Published on:

  10. Acute lymphoblastic leukemia (ALL) is a hematological malignancy characterized by the malignant clonal expansion of lymphoid hematopoietic precursors. It is regulated by various signaling molecules such as cyt...

    Authors: Zixi Hong, Zimeng Wei, Tian Xie, Lin Fu, Jiaxing Sun, Fuling Zhou, Muhammad Jamal, Qiuping Zhang and Liang Shao
    Citation: Journal of Hematology & Oncology 2021 14:48
    Content type: Review Published on:

  11. B Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) is the most common pediatric cancer. Identifying key players involved in proliferation of BCP-ALL cells is crucial to propose new therapeutic targets. Ru...

    Authors: Hélène Jakobczyk, Lydie Debaize, Benoit Soubise, Stéphane Avner, Jérémie Rouger-Gaudichon, Séverine Commet, Yan Jiang, Aurélien A. Sérandour, Anne-Gaëlle Rio, Jason S. Carroll, Christian Wichmann, Michael Lie-a-Ling, Georges Lacaud, Laurent Corcos, Gilles Salbert, Marie-Dominique Galibert…
    Citation: Journal of Hematology & Oncology 2021 14:47
    Content type: Research Published on:

  12. NONO-TFE3 translocation renal cell carcinoma (NONO-TFE3 tRCC) is one subtype of RCCs associated with Xp11.2 translocation/TFE3 gene fusions RCC (Xp11.2 tRCCs). Long non-coding RNA (lncRNA) has attracted great att...

    Authors: Lei Yang, Yi Chen, Ning Liu, QianCheng Shi, Xiaodong Han, Weidong Gan and Dongmei Li
    Citation: Journal of Hematology & Oncology 2021 14:46
    Content type: Research Published on:

    The Correction to this article has been published in Journal of Hematology & Oncology 2021 14:144

  13. The immune system is the core defense against cancer development and progression. Failure of the immune system to recognize and eliminate malignant cells plays an important role in the pathogenesis of cancer. ...

    Authors: Julian A. Marin-Acevedo, ErinMarie O. Kimbrough and Yanyan Lou
    Citation: Journal of Hematology & Oncology 2021 14:45
    Content type: Review Published on:

  15. Transgelin-2 is a 22 kDa actin-binding protein that has been proposed to act as an oncogenic factor, capable of contributing to tumorigenesis in a wide range of human malignancies. However, little is known whe...

    Authors: Hye-Ran Kim, Jeong-Su Park, Jin-Hwa Park, Fatima Yasmin, Chang-Hyun Kim, Se Kyu Oh, Ik-Joo Chung and Chang-Duk Jun
    Citation: Journal of Hematology & Oncology 2021 14:43
    Content type: Research Published on:

  16. The original article [1] contains an error in Fig. 6b for the image of western blot panels.

    Authors: Wen-Tao Wang, Tian-Qi Chen, Zhan-Cheng Zeng, Qi Pan, Wei Huang, Cai Han, Ke Fang, Lin-Yu Sun, Qian-Qian Yang, Dan Wang, Xue-Qun Luo, Yu-Meng Sun and Yue-Qin Chen
    Citation: Journal of Hematology & Oncology 2021 14:42
    Content type: Correction Published on:

    The original article was published in Journal of Hematology & Oncology 2020 13:78

  17. Circular RNAs (circRNAs) are a new class of endogenous regulatory RNAs characterized by covalently closed cyclic structure lacking poly-adenylated tails, and are capable of regulating gene expression at transc...

    Authors: Lijuan Lyu, Shizhen Zhang, Yujiao Deng, Meng Wang, Xinyue Deng, Si Yang, Ying Wu and Zhijun Dai
    Citation: Journal of Hematology & Oncology 2021 14:41
    Content type: Review Published on:

  21. Hetrombopag, a novel thrombopoietin receptor agonist, has been found in phase I studies to increase platelet counts and reduce bleeding risks in adults with immune thrombocytopenia (ITP). This phase III study ...

    Authors: Heng Mei, Xiaofan Liu, Yan Li, Hu Zhou, Ying Feng, Guangxun Gao, Peng Cheng, Ruibin Huang, Linhua Yang, Jianda Hu, Ming Hou, Yazhou Yao, Li Liu, Yi Wang, Depei Wu, Liansheng Zhang…
    Citation: Journal of Hematology & Oncology 2021 14:37
    Content type: Research Published on:

  22. B-cell receptor (BCR) antagonists such as the BTK inhibitor ibrutinib have proven to effectively target chronic lymphocytic leukemia (CLL) tumor cells, leading to impressive response rates in these patients. H...

    Authors: Timothy L. Chen, Bonnie Harrington, Jean Truxall, Ronni Wasmuth, Alexander Prouty, Shelby Sloan, Amy M. Lehman, Deepa Sampath, Eric Orlemans, Robert A. Baiocchi, Lapo Alinari, John C. Byrd, Jennifer A. Woyach and Erin Hertlein
    Citation: Journal of Hematology & Oncology 2021 14:36
    Content type: Letter to the Editor Published on:

  23. Moxetumomab pasudotox is a recombinant CD22-targeting immunotoxin. Here, we present the long-term follow-up analysis of the pivotal, multicenter, open-label trial (NCT01829711) of moxetumomab pasudotox in pati...

    Authors: Robert J. Kreitman, Claire Dearden, Pier Luigi Zinzani, Julio Delgado, Tadeusz Robak, Philipp D. le Coutre, Bjørn T. Gjertsen, Xavier Troussard, Gail J. Roboz, Lionel Karlin, Douglas E. Gladstone, Nataliya Kuptsova-Clarkson, Shiyao Liu, Priti Patel, Federico Rotolo, Emmanuel Mitry…
    Citation: Journal of Hematology & Oncology 2021 14:35
    Content type: Research Published on:

  24. An amendment to this paper has been published and can be accessed via the original article.

    Authors: Musa Yilmaz, Mansour Alfayez, Courtney D. DiNardo, Gautam Borthakur, Tapan M. Kadia, Marina Y. Konopleva, Sanam Loghavi, Rashmi Kanagal-Shamanna, Keyur P. Patel, Elias J. Jabbour, Guillermo Garcia‑Manero, Naveen Pemmaraju, Sherry A. Pierce, Issa Ghayas, Nicholas J. Short, Guillermo Montalban-Bravo…
    Citation: Journal of Hematology & Oncology 2021 14:34
    Content type: Correction Published on:

    The original article was published in Journal of Hematology & Oncology 2020 13:132

  25. An amendment to this paper has been published and can be accessed via the original article.

    Authors: Senlin Zhao, Yushuai Mi, Bingjie Guan, Binbin Zheng, Ping Wei, Yanzi Gu, Zhengxiang Zhang, Sanjun Cai, Ye Xu, Xinxiang Li, Xuefeng He, Xinyang Zhong, Guichao Li, Zhiyu Chen and Dawei Li
    Citation: Journal of Hematology & Oncology 2021 14:33
    Content type: Correction Published on:

    The original article was published in Journal of Hematology & Oncology 2020 13:156

  26. Authors: Dan Jin, Jiwei Guo, Yan Wu, Jing Du, Lijuan Yang, Xiaohong Wang, Weihua Di, Baoguang Hu, Jiajia An, Lingqun Kong, Lei Pan and Guoming Su
    Citation: Journal of Hematology & Oncology 2021 14:32
    Content type: Editor's Note Published on:

    The Research to this article has been published in Journal of Hematology & Oncology 2019 12:135

  27. An amendment to this paper has been published and can be accessed via the original article.

    Authors: Arnold Bolomsky, Meike Vogler, Murat Cem Köse, Caroline A. Heckman, Grégory Ehx, Heinz Ludwig and Jo Caers
    Citation: Journal of Hematology & Oncology 2021 14:31
    Content type: Correction Published on:

    The original article was published in Journal of Hematology & Oncology 2020 13:173

  28. Histone methylation is a key posttranslational modification of chromatin, and its dysregulation affects a wide array of nuclear activities including the maintenance of genome integrity, transcriptional regulat...

    Authors: Guan-Jun Yang, Ming-Hui Zhu, Xin-Jiang Lu, Yan-Jun Liu, Jian-Fei Lu, Chung-Hang Leung, Dik-Lung Ma and Jiong Chen
    Citation: Journal of Hematology & Oncology 2021 14:30
    Content type: Review Published on:

  29. An amendment to this paper has been published and can be accessed via the original article.

    Authors: Zemin Ren, Hildo Lantermans, Annemieke Kuil, Willem Kraan, Fernando Arenzana-Seisdedos, Marie José Kersten, Marcel Spaargaren and Steven T. Pals
    Citation: Journal of Hematology & Oncology 2021 14:29
    Content type: Correction Published on:

    The original article was published in Journal of Hematology & Oncology 2021 14:11

  31. Therapeutic antibodies targeting programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) axis induce potent and durable anti-tumor responses in multiple types of cancers. However, only a subse...

    Authors: Ming Yi, Jing Zhang, Anping Li, Mengke Niu, Yongxiang Yan, Ying Jiao, Suxia Luo, Pengfei Zhou and Kongming Wu
    Citation: Journal of Hematology & Oncology 2021 14:27
    Content type: Research Published on:

  32. CD19-targeted chimeric antigen receptor T (CAR T) cell therapy is a promising option to treat relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL). However, the majority of CAR T-treated patients will...

    Authors: Yun Liang, Hui Liu, Zheming Lu, Wen Lei, Chaoting Zhang, Ping Li, Aibin Liang, Ken H. Young and Wenbin Qian
    Citation: Journal of Hematology & Oncology 2021 14:26
    Content type: Letter to the Editor Published on:

  33. Natural killer/T-cell lymphoma (NKTCL) is a disease with limited treatment options and poor outcomes. Daratumumab monotherapy demonstrated clinical activity in a single-patient case report. We present data fro...

    Authors: Huiqiang Huang, Jun Zhu, Ming Yao, Tae Min Kim, Dok Hyun Yoon, Seok-Goo Cho, Hyeon Seok Eom, Soon Thye Lim, Su-peng Yeh, Yuqin Song, Yok Lam Kwong, Jin Seok Kim, Jie Jin, Yuankai Shi, HyeJin Kim, Min Qing…
    Citation: Journal of Hematology & Oncology 2021 14:25
    Content type: Research Published on:

  34. Mesenchymal stromal cells (MSCs), also known as mesenchymal stem cells, have been intensely investigated for clinical applications within the last decades. However, the majority of registered clinical trials a...

    Authors: Tian Zhou, Zenan Yuan, Jianyu Weng, Duanqing Pei, Xin Du, Chang He and Peilong Lai
    Citation: Journal of Hematology & Oncology 2021 14:24
    Content type: Review Published on:

  35. Fibroblast growth factor receptors (FGFRs) play key roles in promoting the proliferation, differentiation, and migration of cancer cell. Inactivation of FGFRs by tyrosine kinase inhibitors (TKI) has achieved g...

    Authors: Sitong Yue, Yukun Li, Xiaojuan Chen, Juan Wang, Meixiang Li, Yongheng Chen and Daichao Wu
    Citation: Journal of Hematology & Oncology 2021 14:23
    Content type: Review Published on:

  36. Genetic heterogeneity of tumor is closely related to its clonal evolution, phenotypic diversity and treatment resistance, and such heterogeneity has only been characterized at single-cell sub-chromosomal scale...

    Authors: Xianbin Su, Linan Zhao, Yi Shi, Rui Zhang, Qi Long, Shihao Bai, Qing Luo, Yingxin Lin, Xin Zou, Shila Ghazanfar, Kun Tao, Guoliang Yang, Lan Wang, Kun-Yan He, Xiaofang Cui, Jian He…
    Citation: Journal of Hematology & Oncology 2021 14:22
    Content type: Letter to the Editor Published on:

  37. B7-H3, an immune-checkpoint molecule and a transmembrane protein, is overexpressed in non-small cell lung cancer (NSCLC), making it an attractive therapeutic target. Here, we aimed to systematically evaluate t...

    Authors: Jie Liu, Shuo Yang, Bihui Cao, Guangyu Zhou, Fengjuan Zhang, Yuan Wang, Rixin Wang, Lipeng Zhu, Ya Meng, Cong Hu, Hui Liang, Xu Lin, Kangshun Zhu, Guokai Chen, Kathy Qian Luo, Lijun Di…
    Citation: Journal of Hematology & Oncology 2021 14:21
    Content type: Research Published on:

  38. Antibody–drug conjugates (ADCs) are a relatively new class of anticancer agents designed to merge the selectivity of monoclonal antibodies with cell killing properties of chemotherapy. They are commonly descri...

    Authors: Carmen Criscitiello, Stefania Morganti and Giuseppe Curigliano
    Citation: Journal of Hematology & Oncology 2021 14:20
    Content type: Review Published on:

  39. TNBC is the most aggressive breast cancer with higher recurrence and mortality rate than other types of breast cancer. There is an urgent need for identification of therapeutic agents with unique mode of actio...

    Authors: Yahui Ding, Xiaoping Chen, Can Liu, Weizhi Ge, Qin Wang, Xin Hao, Mengmeng Wang, Yue Chen and Quan Zhang
    Citation: Journal of Hematology & Oncology 2021 14:19
    Content type: Research Published on:

  40. Accurate interpretation of BRCA1/2 variants is critical for risk assessment and precise treatment of breast cancer (BC). Hence, the establishment of an ethnicity-based BRCA1/2 variant database of the Chinese popu...

    Authors: Yun Liu, Honglian Wang, Xin Wang, Jiaqi Liu, Junjian Li, Xiang Wang, Yun Zhang, Zhigang Bai, Qinghua Zhou, Ying Wu, Yi Shen, Xiaoling Weng, Fatao Liu, Jiancheng Guo, Lijun Di, Olivier Gires…
    Citation: Journal of Hematology & Oncology 2021 14:18
    Content type: Letter to the Editor Published on:

  41. Exportin 1 (XPO1/CRM1) is a key mediator of nuclear export with relevance to multiple cancers, including chronic lymphocytic leukemia (CLL). Whole exome sequencing has identified hot-spot somatic XPO1 point mutat...

    Authors: Janek S. Walker, Zachary A. Hing, Bonnie Harrington, Jordan Baumhardt, Hatice Gulcin Ozer, Amy Lehman, Brian Giacopelli, Larry Beaver, Katie Williams, Jordan N. Skinner, Casey B. Cempre, Qingxiang Sun, Sharon Shacham, Benjamin R. Stromberg, Matthew K. Summers, Lynne V. Abruzzo…
    Citation: Journal of Hematology & Oncology 2021 14:17
    Content type: Research Published on:

  42. Dysregulation of both mitochondrial biogenesis and mitophagy is critical to sustain oncogenic signaling pathways. However, the mechanism of mitophagy in promoting hepatocellular carcinoma (HCC) progression rem...

    Authors: Yahui Zheng, Chong Huang, Lu Lu, Kangkang Yu, Jing Zhao, Mingquan Chen, Lu Liu, Qingfeng Sun, Zhifei Lin, Jianming Zheng, Jinhong Chen and Jubo Zhang
    Citation: Journal of Hematology & Oncology 2021 14:16
    Content type: Research Published on:

  44. Attributable to its late diagnosis, early metastasis, and poor prognosis, pancreatic cancer remains one of the most lethal diseases worldwide. Unlike other solid tumors, pancreatic cancer harbors ample stromal...

    Authors: Jinxin Tao, Gang Yang, Wenchuan Zhou, Jiangdong Qiu, Guangyu Chen, Wenhao Luo, Fangyu Zhao, Lei You, Lianfang Zheng, Taiping Zhang and Yupei Zhao
    Citation: Journal of Hematology & Oncology 2021 14:14
    Content type: Review Published on:

  45. Several targeted therapies have shown efficacy in patients with advanced gastric cancer (GC) and gastroesophageal junction adenocarcinoma (GEJC), including anti-angiogenic agents and immune checkpoint inhibito...

    Authors: Anwaar Saeed, Robin Park and Weijing Sun
    Citation: Journal of Hematology & Oncology 2021 14:13
    Content type: Review Published on:

  46. Peripheral T cell lymphoma (PTCL) is a rare disease and recent approved drugs for relapsed/refractory (r/r) PTCL provided limited clinical benefit. We conducted this study to evaluate the efficacy and safety o...

    Authors: Yuankai Shi, Jianqiu Wu, Zhen Wang, Liling Zhang, Zhao Wang, Mingzhi Zhang, Hong Cen, Zhigang Peng, Yufu Li, Lei Fan, Ye Guo, Liping Ma, Jie Cui, Yuhuan Gao, Haiyan Yang, Hongyu Zhang…
    Citation: Journal of Hematology & Oncology 2021 14:12
    Content type: Research Published on:

  47. The survival and proliferation of multiple myeloma (MM) cells in the bone marrow (BM) critically depend on interaction with stromal cells expressing the chemokine CXCL12. CXCL12 regulates the homing to the BM ...

    Authors: Zemin Ren, Hildo Lantermans, Annemieke Kuil, Willem Kraan, Fernando Arenzana-Seisdedos, Marie José Kersten, Marcel Spaargaren and Steven T. Pals
    Citation: Journal of Hematology & Oncology 2021 14:11
    Content type: Research Published on:

    The Correction to this article has been published in Journal of Hematology & Oncology 2021 14:29

  48. Programmed death-ligand 1 (PD-L1) on cancer cells engages with programmed cell death-1 (PD-1) on immune cells, contributing to cancer immune escape. For multiple cancer types, the PD-1/PD-L1 axis is the major ...

    Authors: Ming Yi, Mengke Niu, Linping Xu, Suxia Luo and Kongming Wu
    Citation: Journal of Hematology & Oncology 2021 14:10
    Content type: Review Published on:

  49. Key hepatic molecules linking gut dysbiosis and hepatocarcinogenesis remain largely unknown. Gut-derived gut microbiota contains pathogen-associated molecular patterns (PAMPs) that may circulate into the liver...

    Authors: Yi Zhou, Liang Hu, Wenqing Tang, Dongping Li, Lijie Ma, Hongchun Liu, Shuncai Zhang, Xiaojie Zhang, Ling Dong, Xizhong Shen, She Chen, Ruyi Xue and Si Zhang
    Citation: Journal of Hematology & Oncology 2021 14:9
    Content type: Research Published on:
JHO logo
Submit manuscript

Follow

Annual Journal Metrics

  • 2022 Citation Impact
    28.5 - 2-year Impact Factor
    23.1 - 5-year Impact Factor
    4.045 - SNIP (Source Normalized Impact per Paper)
    6.046 - SJR (SCImago Journal Rank)

    2023 Speed
    5 days submission to first editorial decision for all manuscripts (Median)
    59 days submission to accept (Median)

    2023 Usage 
    3,173,795 downloads
    2,671 Altmetric mentions

On the blog

Institutional membership

Visit the membership page to check if your institution is a member and learn how you could save on article-processing charges (APCs).

Funding your APC

​​​​​​​Open access funding and policy support by SpringerOpen​​

​​​​We offer a free open access support service to make it easier for you to discover and apply for article-processing charge (APC) funding. Learn more here. 

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us